Bordet R - Search Results

1

Neutrophils in tPA-induced hemorrhagic transformations: Main culprit, accomplice or innocent bystander?

Ouk T, Potey C, Maestrini I, Petrault M, Mendyk AM, Leys D, Bordet R, Gautier S. Ouk T, et al. Among authors: bordet r. Pharmacol Ther. 2019 Feb;194:73-83. doi: 10.1016/j.pharmthera.2018.09.005. Epub 2018 Sep 18. Pharmacol Ther. 2019. PMID: 30240634 Review.

2

[Concern of pharmacovigilance: proarrhythmic effects of medications in current use].

Caron J, Gautier S, Couderc E, Bordet R. Caron J, et al. Among authors: bordet r. Arch Pediatr. 1999;6 Suppl 2:231s-232s. doi: 10.1016/s0929-693x(99)80422-9. Arch Pediatr. 1999. PMID: 10370490 French. No abstract available.

3

Increase in endogenous brain superoxide dismutase as a potential mechanism of lipopolysaccharide-induced brain ischemic tolerance.

Bordet R, Deplanque D, Maboudou P, Puisieux F, Pu Q, Robin E, Martin A, Bastide M, Leys D, Lhermitte M, Dupuis B. Bordet R, et al. J Cereb Blood Flow Metab. 2000 Aug;20(8):1190-6. doi: 10.1097/00004647-200008000-00004. J Cereb Blood Flow Metab. 2000. PMID: 10950379

4

Analysis of the direct cost of adverse drug reactions in hospitalised patients.

Bordet R, Gautier S, Le Louet H, Dupuis B, Caron J. Bordet R, et al. Eur J Clin Pharmacol. 2001 Mar;56(12):935-41. doi: 10.1007/s002280000260. Eur J Clin Pharmacol. 2001. PMID: 11317484

5

Stroke prevention: management of modifiable vascular risk factors.

Leys D, Deplanque D, Mounier-Vehier C, Mackowiak-Cordoliani MA, Lucas C, Bordet R. Leys D, et al. Among authors: bordet r. J Neurol. 2002 May;249(5):507-17. doi: 10.1007/s004150200057. J Neurol. 2002. PMID: 12021938 Review.

6

Hypolipemic agents for stroke prevention.

Leys D, Deplanque D, Lucas C, Bordet R. Leys D, et al. Among authors: bordet r. Clin Exp Hypertens. 2002 Oct-Nov;24(7-8):573-94. doi: 10.1081/ceh-120015334. Clin Exp Hypertens. 2002. PMID: 12450233 Review.

7

The cost of adverse drug reactions.

Gautier S, Bachelet H, Bordet R, Caron J. Gautier S, et al. Among authors: bordet r. Expert Opin Pharmacother. 2003 Mar;4(3):319-26. doi: 10.1517/14656566.4.3.319. Expert Opin Pharmacother. 2003. PMID: 12614184 Review.

8

Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment.

Deplanque D, Gelé P, Pétrault O, Six I, Furman C, Bouly M, Nion S, Dupuis B, Leys D, Fruchart JC, Cecchelli R, Staels B, Duriez P, Bordet R. Deplanque D, et al. Among authors: bordet r. J Neurosci. 2003 Jul 16;23(15):6264-71. doi: 10.1523/JNEUROSCI.23-15-06264.2003. J Neurosci. 2003. PMID: 12867511 Free PMC article.

9

Involvement of thrombolysis in recombinant tissue plasminogen activator-induced cerebral hemorrhages and effect on infarct volume and postischemic endothelial function.

Gautier S, Petrault O, Gele P, Laprais M, Bastide M, Bauters A, Deplanque D, Jude B, Caron J, Bordet R. Gautier S, et al. Among authors: bordet r. Stroke. 2003 Dec;34(12):2975-9. doi: 10.1161/01.STR.0000101914.62066.7B. Epub 2003 Nov 13. Stroke. 2003. PMID: 14615621

10

The neuroprotective effect of the antioxidant flavonoid derivate di-tert-butylhydroxyphenyl is parallel to the preventive effect on post-ischemic Kir2.x impairment but not to post-ischemic endothelial dysfunction.

Pétrault O, Bastide M, Cotelle N, Gelé P, Gautier S, Laprais M, Vamecq J, Duriez P, Bordet R. Pétrault O, et al. Among authors: bordet r. Naunyn Schmiedebergs Arch Pharmacol. 2004 Nov;370(5):395-403. doi: 10.1007/s00210-004-0966-x. Epub 2004 Oct 19. Naunyn Schmiedebergs Arch Pharmacol. 2004. PMID: 15502971

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

420 results

Search Page